Abstract
Background: B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) can activate signaling pathways by binding to specific receptors. BR3 (BAFF receptor) shows a unique selectivity for BAFF ligand, while B-cell maturation antigen (BCMA) exhibits a stronger interaction between APRIL-BCMA rather than BAFF-BCMA interaction.
Objective: The combined domains were fused with IgG1 Fc to better understand which domain affects the selective interaction of the receptor with BAFF and APRIL.
Methods: Since BR3 and BCMA both contain cysteine-rich repeat domains (CRD) with DxL motif, the binding domains of BR3 and BCMA were segmented into two parts in this study. BR3-1 (CFDLLVRHGVAC) and BCMA-1 (YFDSLLHACIPC) contained the conservative DxL motif, while BR3-2 (GLLRTPRPKPA) and BCMA-2 (QLRCSSNTPPLT) were adjacent to the CRDs yet still joined with BR3-1 and BCMA-1. Affinity between all possible combinations was then tested.
Results: The affinity of BR3-1-BCMA-2-Fc and BR3-1-BR3-2-Fc for BAFF was higher than BCMA-1-BR3-2-Fc and BCMA-1-BCMA-2-Fc. Moreover, BR3-1-BCMA-2-Fc and BCMA-1-BCMA- 2-Fc had affinity for APRIL, while BR3-1-BR3-2-Fc and BCMA-1-BR3-2-Fc hardly interacted with APRIL.
Conclusion: BR3-1 region played a key role for interaction with BAFF, while BCMA-1 region exhibited weaker binding with BAFF. BCMA-2 region having an α-helix might contribute towards selectivity of APRIL-BCMA binding and BR3-2 rigid region had deleterious effects on the APRIL-BR3 interaction. These results provide comprehensive insights of the mechanism of selective interactions, and may promote specific antagonist design in the future.
Keywords: BAFF, APRIL, BR3, BCMA, selective binding, mechanism.
Graphical Abstract
[1]
Mackay, F.; Schneider, P.; Rennert, P.; Browning, J. BAFF AND APRIL: A tutorial on B cell survival. Annu. Rev. Immunol., 2003, 21, 231-264.[http://dx.doi.org/10.1146/annurev.immunol.21.120601.141152] [PMID: 12427767]
[2]
Mackay, F.; Ambrose, C. The TNF family members BAFF and APRIL: The growing complexity. Cytokine Growth Factor Rev., 2003, 14(3-4), 311-324.[http://dx.doi.org/10.1016/S1359-6101(03)00023-6] [PMID: 12787568]
[3]
Schneider, P.; MacKay, F.; Steiner, V.; Hofmann, K.; Bodmer, J.L.; Holler, N.; Ambrose, C.; Lawton, P.; Bixler, S.; Acha-Orbea, H.; Valmori, D.; Romero, P.; Werner-Favre, C.; Zubler, R.H.; Browning, J.L.; Tschopp, J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med., 1999, 189(11), 1747-1756.[http://dx.doi.org/10.1084/jem.189.11.1747] [PMID: 10359578]
[4]
Bodmer, J.L.; Schneider, P.; Tschopp, J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci., 2002, 27(1), 19-26.[http://dx.doi.org/10.1016/S0968-0004(01)01995-8] [PMID: 11796220]
[5]
Daridon, C.; Youinou, P.; Pers, J.O. BAFF, APRIL, TWE-PRIL: who’s who? Autoimmun. Rev., 2008, 7(4), 267-271.[http://dx.doi.org/10.1016/j.autrev.2007.05.002] [PMID: 18295728]
[6]
Craxton, A.; Magaletti, D.; Ryan, E.J.; Clark, E.A. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood, 2003, 101(11), 4464-4471.[http://dx.doi.org/10.1182/blood-2002-10-3123] [PMID: 12531790]
[7]
Karpusas, M.; Cachero, T.G.; Qian, F.; Boriack-Sjodin, A.; Mullen, C.; Strauch, K.; Hsu, Y.M.; Kalled, S.L. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J. Mol. Biol., 2002, 315(5), 1145-1154.[http://dx.doi.org/10.1006/jmbi.2001.5296] [PMID: 11827482]
[8]
Rolink, A.G.; Tschopp, J.; Schneider, P.; Melchers, F. BAFF is a survival and maturation factor for mouse B cells. Eur. J. Immunol., 2002, 32(7), 2004-2010.[http://dx.doi.org/10.1002/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5] [PMID: 12115621]
[9]
Shulga-Morskaya, S.; Dobles, M.; Walsh, M.E.; Ng, L.G.; MacKay, F.; Rao, S.P.; Kalled, S.L.; Scott, M.L. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol., 2004, 173(4), 2331-2341.[http://dx.doi.org/10.4049/jimmunol.173.4.2331] [PMID: 15294946]
[10]
Ng, L.G.; Mackay, C.R.; Mackay, F. The BAFF/APRIL system: Life beyond B lymphocytes. Mol. Immunol., 2005, 42(7), 763-772.[http://dx.doi.org/10.1016/j.molimm.2004.06.041] [PMID: 15829264]
[11]
Gardam, S.; Brink, R. Non-Canonical NF-κB Signaling Initiated by BAFF Influences B Cell Biology at Multiple Junctures. Front. Immunol., 2014, 4, 509.[http://dx.doi.org/10.3389/fimmu.2013.00509] [PMID: 24432023]
[12]
Hahne, M.; Kataoka, T.; Schröter, M.; Hofmann, K.; Irmler, M.; Bodmer, J.L.; Schneider, P.; Bornand, T.; Holler, N.; French, L.E.; Sordat, B.; Rimoldi, D.; Tschopp, J. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med., 1998, 188(6), 1185-1190.[http://dx.doi.org/10.1084/jem.188.6.1185] [PMID: 9743536]
[13]
Roth, W.; Wagenknecht, B.; Klumpp, A.; Naumann, U.; Hahne, M.; Tschopp, J.; Weller, M. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ., 2001, 8(4), 403-410.[http://dx.doi.org/10.1038/sj.cdd.4400827] [PMID: 11550092]
[14]
Mackay, F.; Tangye, S.G. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr. Opin. Pharmacol., 2004, 4(4), 347-354.[http://dx.doi.org/10.1016/j.coph.2004.02.009] [PMID: 15251127]
[15]
López-Fraga, M.; Fernández, R.; Albar, J.P.; Hahne, M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep., 2001, 2(10), 945-951.[http://dx.doi.org/10.1093/embo-reports/kve198] [PMID: 11571266]
[16]
Yu, G.; Boone, T.; Delaney, J.; Hawkins, N.; Kelley, M.; Ramakrishnan, M.; McCabe, S.; Qiu, W.R.; Kornuc, M.; Xia, X.Z.; Guo, J.; Stolina, M.; Boyle, W.J.; Sarosi, I.; Hsu, H.; Senaldi, G.; Theill, L.E. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol., 2000, 1(3), 252-256.[http://dx.doi.org/10.1038/79802] [PMID: 10973284]
[17]
Mackay, F.; Schneider, P. Cracking the BAFF code. Nat. Rev. Immunol., 2009, 9(7), 491-502.[http://dx.doi.org/10.1038/nri2572] [PMID: 19521398]
[18]
Dickinson, G.S.; Sun, G.; Bram, R.J.; Alugupalli, K.R.; Efficient, B. Efficient B cell responses to Borrelia hermsii infection depend on BAFF and BAFFR but not TACI. Infect. Immun., 2014, 82(1), 453-459.[http://dx.doi.org/10.1128/IAI.01147-13] [PMID: 24218480]
[19]
Mackay, F.; Silveira, P.A.; Brink, R. B cells and the BAFF/APRIL axis: Fast-forward on autoimmunity and signaling. Curr. Opin. Immunol., 2007, 19(3), 327-336.[http://dx.doi.org/10.1016/j.coi.2007.04.008] [PMID: 17433868]
[20]
Schiemann, B.; Gommerman, J.L.; Vora, K.; Cachero, T.G.; Shulga-Morskaya, S.; Dobles, M.; Frew, E.; Scott, M.L. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science, 2001, 293(5537), 2111-2114.[http://dx.doi.org/10.1126/science.1061964] [PMID: 11509691]
[21]
Hayden, M.S.; Ghosh, S. Shared principles in NF-kappaB signaling. Cell, 2008, 132(3), 344-362.[http://dx.doi.org/10.1016/j.cell.2008.01.020] [PMID: 18267068]
[22]
Cheng, Y.; Yan, S.; Zhao, W.; Huang, Q.; Lian, L.; Wei, W. The effect of BLyS on the activity of peripheral B lymphocytes mediated by BLyS receptors in patients with systemic lupus erythematosus. Scand. J. Clin. Lab. Invest., 2013, 73(2), 141-147.[http://dx.doi.org/10.3109/00365513.2012.756120] [PMID: 23336587]
[23]
Vincent, F.B.; Morand, E.F.; Schneider, P.; Mackay, F. The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol., 2014, 10(6), 365-373.[http://dx.doi.org/10.1038/nrrheum.2014.33] [PMID: 24614588]
[24]
Wei, F.; Chang, Y.; Wei, W. The role of BAFF in the progression of rheumatoid arthritis. Cytokine, 2015, 76(2), 537-544.[http://dx.doi.org/10.1016/j.cyto.2015.07.014] [PMID: 26198030]
[25]
Vincent, F.B.; Saulep-Easton, D.; Figgett, W.A.; Fairfax, K.A.; Mackay, F. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev., 2013, 24(3), 203-215.[http://dx.doi.org/10.1016/j.cytogfr.2013.04.003] [PMID: 23684423]
[26]
Thompson, N.; Isenberg, D.A.; Jury, E.C.; Ciurtin, C. Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjögren’s syndrome. Rheumatology (Oxford), 2016, 55(9), 1548-1555.[http://dx.doi.org/10.1093/rheumatology/kev420] [PMID: 26790457]
[27]
Hymowitz, S.G.; Patel, D.R.; Wallweber, H.J.; Runyon, S.; Yan, M.; Yin, J.; Shriver, S.K.; Gordon, N.C.; Pan, B.; Skelton, N.J.; Kelley, R.F.; Starovasnik, M.A. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J. Biol. Chem., 2005, 280(8), 7218-7227.[http://dx.doi.org/10.1074/jbc.M411714200] [PMID: 15542592]
[28]
Gross, J.A.; Johnston, J.; Mudri, S.; Enselman, R.; Dillon, S.R.; Madden, K.; Xu, W.; Parrish-Novak, J.; Foster, D.; Lofton-Day, C.; Moore, M.; Littau, A.; Grossman, A.; Haugen, H.; Foley, K.; Blumberg, H.; Harrison, K.; Kindsvogel, W.; Clegg, C.H. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature, 2000, 404(6781), 995-999.[http://dx.doi.org/10.1038/35010115] [PMID: 10801128]
[29]
Bossen, C.; Schneider, P. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol., 2006, 18(5), 263-275.[http://dx.doi.org/10.1016/j.smim.2006.04.006] [PMID: 16914324]
[30]
Schuepbach-Mallepell, S.; Das, D.; Willen, L.; Vigolo, M.; Tardivel, A.; Lebon, L.; Kowalczyk-Quintas, C.; Nys, J.; Smulski, C.; Zheng, T.S.; Maskos, K.; Lammens, A.; Jiang, X.; Hess, H.; Tan, S.L.; Schneider, P. Stoichiometry of heteromeric BAFF and APRIL cytokines dictates their receptor binding and signaling properties. J. Biol. Chem., 2015, 290(26), 16330-16342.[http://dx.doi.org/10.1074/jbc.M115.661405] [PMID: 25953898]
[31]
Thompson, J.S.; Bixler, S.A.; Qian, F.; Vora, K.; Scott, M.L.; Cachero, T.G.; Hession, C.; Schneider, P.; Sizing, I.D.; Mullen, C.; Strauch, K.; Zafari, M.; Benjamin, C.D.; Tschopp, J.; Browning, J.L.; Ambrose, C. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science, 2001, 293(5537), 2108-2111.[http://dx.doi.org/10.1126/science.1061965] [PMID: 11509692]
[32]
Yan, M.; Brady, J.R.; Chan, B.; Lee, W.P.; Hsu, B.; Harless, S.; Cancro, M.; Grewal, I.S.; Dixit, V.M. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol., 2001, 11(19), 1547-1552.[http://dx.doi.org/10.1016/S0960-9822(01)00481-X] [PMID: 11591325]
[33]
Smulski, C.R.; Kury, P.; Seidel, L.M.; Staiger, H.S.; Edinger, A.K.; Willen, L.; Seidl, M.; Hess, H.; Salzer, U.; Rolink, A.G.; Rizzi, M.; Schneider, P.; Eibel, H. BAFF- and TACI-Dependent Processing of BAFFR by ADAM Proteases Regulates the Survival of B Cells. Cell Rep., 2017, 18(9), 2189-2202.[http://dx.doi.org/10.1016/j.celrep.2017.02.005] [PMID: 28249164]
[34]
O’Connor, B.P.; Raman, V.S.; Erickson, L.D.; Cook, W.J.; Weaver, L.K.; Ahonen, C.; Lin, L.L.; Mantchev, G.T.; Bram, R.J.; Noelle, R.J. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med., 2004, 199(1), 91-98.[http://dx.doi.org/10.1084/jem.20031330] [PMID: 14707116]
[35]
Ng, L.G.; Sutherland, A.P.R.; Newton, R.; Qian, F.; Cachero, T.G.; Scott, M.L.; Thompson, J.S.; Wheway, J.; Chtanova, T.; Groom, J.; Sutton, I.J.; Xin, C.; Tangye, S.G.; Kalled, S.L.; Mackay, F.; Mackay, C.R. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol., 2004, 173(2), 807-817.[http://dx.doi.org/10.4049/jimmunol.173.2.807] [PMID: 15240667]
[36]
Fu, L.; Lin-Lee, Y.C.; Pham, L.V.; Tamayo, A.T.; Yoshimura, L.C.; Ford, R.J. BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood, 2009, 113(19), 4627-4636.[http://dx.doi.org/10.1182/blood-2008-10-183467] [PMID: 19258594]
[37]
Yang, S.; Li, J.Y.; Xu, W. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma. Crit. Rev. Oncol. Hematol., 2014, 91(2), 113-122.[http://dx.doi.org/10.1016/j.critrevonc.2014.02.004] [PMID: 24629840]
[38]
Peperzak, V.; Vikstrom, I.; Walker, J.; Glaser, S.P.; LePage, M.; Coquery, C.M.; Erickson, L.D.; Fairfax, K.; Mackay, F.; Strasser, A.; Nutt, S.L.; Tarlinton, D.M. Mcl-1 is essential for the survival of plasma cells (vol 14, pg 290, 2013). Nat. Immunol., 2013, 14(8), 877-877.[http://dx.doi.org/10.1038/ni0813-877c]
[39]
Laurent, S.A.; Hoffmann, F.S.; Kuhn, P.H.; Cheng, Q.; Chu, Y.; Schmidt-Supprian, M.; Hauck, S.M.; Schuh, E.; Krumbholz, M.; Rübsamen, H.; Wanngren, J.; Khademi, M.; Olsson, T.; Alexander, T.; Hiepe, F.; Pfister, H.W.; Weber, F.; Jenne, D.; Wekerle, H.; Hohlfeld, R.; Lichtenthaler, S.F.; Meinl, E. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun., 2015, 6, 7333.[http://dx.doi.org/10.1038/ncomms8333] [PMID: 26065893]
[40]
Bu, D.X.; Singh, R.; Choi, E.E.; Ruella, M.; Nunez-Cruz, S.; Mansfield, K.G.; Bennett, P.; Barton, N.; Wu, Q.; Zhang, J.; Wang, Y.; Wei, L.; Cogan, S.; Ezell, T.; Joshi, S.; Latimer, K.J.; Granda, B.; Tschantz, W.R.; Young, R.M.; Huet, H.A.; Richardson, C.J.; Milone, M.C. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget, 2018, 9(40), 25764-25780.[http://dx.doi.org/10.18632/oncotarget.25359] [PMID: 29899820]
[41]
Avery, D.T.; Kalled, S.L.; Ellyard, J.I.; Ambrose, C.; Bixler, S.A.; Thien, M.; Brink, R.; Mackay, F.; Hodgkin, P.D.; Tangye, S.G. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest., 2003, 112(2), 286-297.[http://dx.doi.org/10.1172/JCI18025] [PMID: 12865416]
[42]
Treml, L.S.; Carlesso, G.; Hoek, K.L.; Stadanlick, J.E.; Kambayashi, T.; Bram, R.J.; Cancro, M.P.; Khan, W.N. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J. Immunol., 2007, 178(12), 7531-7539.[http://dx.doi.org/10.4049/jimmunol.178.12.7531] [PMID: 17548587]
[43]
Groom, J.R.; Fletcher, C.A.; Walters, S.N.; Grey, S.T.; Watt, S.V.; Sweet, M.J.; Smyth, M.J.; Mackay, C.R.; Mackay, F. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med., 2007, 204(8), 1959-1971.[http://dx.doi.org/10.1084/jem.20062567] [PMID: 17664289]
[44]
Figgett, W.A.; Fairfax, K.; Vincent, F.B.; Le Page, M.A.; Katik, I.; Deliyanti, D.; Quah, P.S.; Verma, P.; Grumont, R.; Gerondakis, S.; Hertzog, P.; O’Reilly, L.A.; Strasser, A.; Mackay, F. The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death. Immunity, 2013, 39(3), 573-583.[http://dx.doi.org/10.1016/j.immuni.2013.05.019] [PMID: 24012421]
[45]
Zhao, L.D.; Li, Y.; Smith, M.F., Jr; Wang, J.S.; Zhang, W.; Tang, F.L.; Tian, X.P.; Wang, H.Y.; Zhang, F.C.; Ba, D.N.; He, W.; Zhang, X. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus, 2010, 19(13), 1534-1549.[http://dx.doi.org/10.1177/0961203310375268] [PMID: 20974656]
[46]
Mantchev, G.T.; Cortesão, C.S.; Rebrovich, M.; Cascalho, M.; Bram, R.J. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J. Immunol., 2007, 179(4), 2282-2288.[http://dx.doi.org/10.4049/jimmunol.179.4.2282] [PMID: 17675489]
[47]
Figgett, W.A.; Deliyanti, D.; Fairfax, K.A.; Quah, P.S.; Wilkinson-Berka, J.L.; Mackay, F. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. J. Autoimmun., 2015, 61, 9-16.[http://dx.doi.org/10.1016/j.jaut.2015.04.007] [PMID: 26027434]
[48]
Bossen, C.; Cachero, T.G.; Tardivel, A.; Ingold, K.; Willen, L.; Dobles, M.; Scott, M.L.; Maquelin, A.; Belnoue, E.; Siegrist, C.A.; Chevrier, S.; Acha-Orbea, H.; Leung, H.; Mackay, F.; Tschopp, J.; Schneider, P. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood, 2008, 111(3), 1004-1012.[http://dx.doi.org/10.1182/blood-2007-09-110874] [PMID: 17942754]
[49]
Mackay, F.; Schneider, P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev., 2008, 19(3-4), 263-276.[http://dx.doi.org/10.1016/j.cytogfr.2008.04.006] [PMID: 18514565]
[50]
Kim, H.M.; Yu, K.S.; Lee, M.E.; Shin, D.R.; Kim, Y.S.; Paik, S.G.; Yoo, O.J.; Lee, H.; Lee, J.O. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat. Struct. Biol., 2003, 10(5), 342-348.[http://dx.doi.org/10.1038/nsb925] [PMID: 12715002]
[51]
Starling, G.C.; Kiener, P.A.; Aruffo, A.; Bajorath, J. Analysis of the ligand binding site in Fas (CD95) by site-directed mutagenesis and comparison with TNFR and CD40. Biochemistry, 1998, 37(11), 3723-3726.[http://dx.doi.org/10.1021/bi972959d] [PMID: 9521690]
[52]
Obmolova, G.; Teplyakov, A.; Malia, T.J.; Wunderler, N.; Kwok, D.; Barone, L.; Sweet, R.; Ort, T.; Scully, M.; Gilliland, G.L. Epitope-dependent mechanisms of CD27 neutralization revealed by X-ray crystallography. Mol. Immunol., 2017, 83, 92-99.[http://dx.doi.org/10.1016/j.molimm.2017.01.005] [PMID: 28119207]
[53]
Mukai, Y.; Shibata, H.; Nakamura, T.; Yoshioka, Y.; Abe, Y.; Nomura, T.; Taniai, M.; Ohta, T.; Ikemizu, S.; Nakagawa, S.; Tsunoda, S.; Kamada, H.; Yamagata, Y.; Tsutsumi, Y. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J. Mol. Biol., 2009, 385(4), 1221-1229.[http://dx.doi.org/10.1016/j.jmb.2008.11.053] [PMID: 19084540]
[54]
Byla, P.; Andersen, M.H.; Holtet, T.L.; Jacobsen, H.; Munch, M.; Gad, H.H.; Thøgersen, H.C.; Hartmann, R. Selection of a novel and highly specific tumor necrosis factor alpha (TNFalpha) antagonist: insight from the crystal structure of the antagonist-TNFalpha complex. J. Biol. Chem., 2010, 285(16), 12096-12100.[http://dx.doi.org/10.1074/jbc.M109.063305] [PMID: 20179326]
[55]
Day, E.S.; Cachero, T.G.; Qian, F.; Sun, Y.; Wen, D.; Pelletier, M.; Hsu, Y.M.; Whitty, A. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry, 2005, 44(6), 1919-1931.[http://dx.doi.org/10.1021/bi048227k] [PMID: 15697217]
[56]
Liu, Y.; Hong, X.; Kappler, J.; Jiang, L.; Zhang, R.; Xu, L.; Pan, C.H.; Martin, W.E.; Murphy, R.C.; Shu, H.B.; Dai, S.; Zhang, G. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature, 2003, 423(6935), 49-56.[http://dx.doi.org/10.1038/nature01543] [PMID: 12721620]
[57]
Wallweber, H.J.; Compaan, D.M.; Starovasnik, M.A.; Hymowitz, S.G. The crystal structure of a proliferation-inducing ligand, APRIL. J. Mol. Biol., 2004, 343(2), 283-290.[http://dx.doi.org/10.1016/j.jmb.2004.08.040] [PMID: 15451660]
[58]
Wang, H.; Marsters, S.A.; Baker, T.; Chan, B.; Lee, W.P.; Fu, L.; Tumas, D.; Yan, M.; Dixit, V.M.; Ashkenazi, A.; Grewal, I.S. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immunol., 2001, 2(7), 632-637.[http://dx.doi.org/10.1038/89782] [PMID: 11429548]
[59]
Lenert, A.; Lenert, P. Current and emerging treatment options for ANCA-associated vasculitis: Potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des. Devel. Ther., 2015, 9, 333-347.[http://dx.doi.org/10.2147/DDDT.S67264] [PMID: 25609919]
[60]
Stohl, W.; Hiepe, F.; Latinis, K.M.; Thomas, M.; Scheinberg, M.A.; Clarke, A.; Aranow, C.; Wellborne, F.R.; Abud-Mendoza, C.; Hough, D.R.; Pineda, L.; Migone, T.S.; Zhong, Z.J.; Freimuth, W.W.; Chatham, W.W. BLISS-52 Study Group; BLISS-76 Study Group. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum., 2012, 64(7), 2328-2337.[http://dx.doi.org/10.1002/art.34400] [PMID: 22275291]
[61]
Hahn, B.H. Belimumab for systemic lupus erythematosus. N. Engl. J. Med., 2013, 368(16), 1528-1535.[http://dx.doi.org/10.1056/NEJMct1207259] [PMID: 23594005]
[62]
Halpern, W. G.; Lappin, P.; Zanardi, T.; Cai, W.; Corcoran, M.; Zhong, J.; Baker, K. P. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicological sciences : an official journal of the Society of Toxicology., 2006, 91(2), 586-599.
[63]
Furie, R.; Petri, M.; Zamani, O.; Cervera, R.; Wallace, D.J.; Tegzová, D.; Sanchez-Guerrero, J.; Schwarting, A.; Merrill, J.T.; Chatham, W.W.; Stohl, W.; Ginzler, E.M.; Hough, D.R.; Zhong, Z.J.; Freimuth, W.; van Vollenhoven, R.F.; Grp, B-S. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum., 2011, 63(12), 3918-3930.[http://dx.doi.org/10.1002/art.30613] [PMID: 22127708]
[64]
Navarra, S.V.; Guzmán, R.M.; Gallacher, A.E.; Hall, S.; Levy, R.A.; Jimenez, R.E.; Li, E.K.; Thomas, M.; Kim, H.Y.; León, M.G.; Tanasescu, C.; Nasonov, E.; Lan, J.L.; Pineda, L.; Zhong, Z.J.; Freimuth, W.; Petri, M.A. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet, 2011, 377(9767), 721-731.[http://dx.doi.org/10.1016/S0140-6736(10)61354-2] [PMID: 21296403]
[65]
Manzi, S.; Sánchez-Guerrero, J.; Merrill, J.T.; Furie, R.; Gladman, D.; Navarra, S.V.; Ginzler, E.M.; D’Cruz, D.P.; Doria, A.; Cooper, S.; Zhong, Z.J.; Hough, D.; Freimuth, W.; Petri, M.A. BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann. Rheum. Dis., 2012, 71(11), 1833-1838.[http://dx.doi.org/10.1136/annrheumdis-2011-200831] [PMID: 22550315]
[66]
Rovin, B.H.; Dooley, M.A.; Radhakrishnan, J.; Ginzler, E.M.; Forrester, T.D.; Anderson, P.W. The impact of tabalumab on the kidney in systemic lupus erythematosus: Results from two phase 3 randomized, clinical trials. Lupus, 2016, 25(14), 1597-1601.[http://dx.doi.org/10.1177/0961203316650734] [PMID: 27220348]
[67]
Zhao, Y.; Hao, X.; Feng, J.; Shen, B.; Wei, J.; Sun, J. The comparison of BLyS-binding peptides from phage display library and computer-aided design on BLyS-TACI interaction. Int. Immunopharmacol., 2015, 24(2), 219-223.[http://dx.doi.org/10.1016/j.intimp.2014.12.013] [PMID: 25533501]
[68]
Liu, F.; Su, L.; Chen, Z.; Feng, D.; Wei, J.; Sun, J. Construction of small molecular CTLA4 analogs with CD80-binding affinity. Biochem. Biophys. Res. Commun., 2019, 513(3), 694-700.[http://dx.doi.org/10.1016/j.bbrc.2019.04.041] [PMID: 30987824]
[69]
Chenna, R.; Sugawara, H.; Koike, T.; Lopez, R.; Gibson, T.J.; Higgins, D.G.; Thompson, J.D. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res., 2003, 31(13), 3497-3500.[http://dx.doi.org/10.1093/nar/gkg500] [PMID: 12824352]
[70]
Fiser, A.; Sali, A. Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol., 2003, 374, 461-491.[http://dx.doi.org/10.1016/S0076-6879(03)74020-8] [PMID: 14696385]
[71]
Laskowski, R.A.; MacArthur, M.W.; Moss, D.S.; Thornton, J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst., 1993, 26(2), 283-291.[http://dx.doi.org/10.1107/S0021889892009944]
[72]
Ahmed, B.; Ali Ashfaq, U.; Usman Mirza, M. Medicinal plant phytochemicals and their inhibitory activities against pancreatic lipase: molecular docking combined with molecular dynamics simulation approach. Nat. Prod. Res., 2018, 32(10), 1123-1129.[http://dx.doi.org/10.1080/14786419.2017.1320786] [PMID: 28446025]
[73]
Fu, X.; Xuan, L.; Wang, Y.; Wei, J.; Sun, J. Molecular mechanism of the affinity interactions between BAFF and its peptides by molecular simulations. Protein Pept. Lett., 2015, 22(11), 992-999.[http://dx.doi.org/10.2174/0929866522666150824145607] [PMID: 26299997]
[74]
Zheng, C.; Zhang, X.; Zhao, Z.; Hao, X.; Wei, J.; Sun, J. Selective binding BAFF/APRIL by the in and outside conservative region of BCMA. Protein Pept. Lett., 2017, 24(6), 489-494.[http://dx.doi.org/10.2174/0929866524666170301115209] [PMID: 28260502]
[75]
Fu, X.G.; Mao, Z.; Li, S.M.; Guan, Y.Y.; Jian, X.D.; Sun, J.; Wei, J. Molecular mechanism of the selectivity between BAFF/APRIL and their receptors by molecular simulations. Mol. Simul., 2017, 43(8), 590-598.[http://dx.doi.org/10.1080/08927022.2017.1279281]
Related Books
Aromatherapy: The Science of Essential Oils
In Vitro Propagation and Secondary Metabolite Production from Medicinal Plants: Current Trends (Part 2)
Micropropagation of Medicinal Plants
Software and Programming Tools in Pharmaceutical Research
Biotechnology and Drug Development for Targeting Human Diseases
In Vitro Propagation and Secondary Metabolite Production from Medicinal Plants: Current Trends (Part 1)
Molecular and Physiological Insights into Plant Stress Tolerance and Applications in Agriculture- Part 2
Micropropagation of Medicinal Plants
Genome Editing in Bacteria (Part 1)
Data Science for Agricultural Innovation and Productivity
Article Metrics
41